MOLOGEN AG raises funds for clinical trials by increasing

share capital

Through an increase in capital share, MOLOGEN AG (ISIN DE0006637200) has raised funds for further clinical studies. A total of 683,800 shares were placed with Absolute Capital Management in Spain with no rights issue. The issue price was based on the average market price of the period of 10 trading days prior to the corporate action. MOLOGEN’s subscribed capital is now increased by 9 per cent to 8,056,131 Euro. The increase in share capital has been recorded at the register of companies.

With the funds thus raised, MOLOGEN plans to finance further clinical trials in the area of cancer treatment. In addition, new products based on MIDGE and dSLIM will undergo further clinical tests. With these activities, MOLOGEN consistently pursues its business strategy of developing innovative products for major pharmaceuticals partners.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview